Zoetis

What Zoetis does

Zoetis is the world's leading animal health company, publicly traded on the NYSE under ZTS since its 2013 spin-off from Pfizer. It develops and commercializes medicines, vaccines, diagnostics, biopharmaceuticals, genetic testing services, and digital solutions for veterinarians, livestock producers, and pet owners across 8 species in more than 100 countries. Core franchises include first-in-class monoclonal antibody therapies (Librela for canine OA pain, Solensia for feline OA pain, Cytopoint for atopic dermatitis), parasiticides (Simparica Trio, Revolution Plus), dermatology products (Apoquel), livestock vaccines and anti-infectives (BOVI-SHIELD, INFORCE 3, Draxxin KP), and AI-powered diagnostic platforms (Vetscan Imagyst, Vetscan OptiCell, Zoetis Virtual Laboratory). Revenue derives from one-time product sales, recurring diagnostic consumables, usage-based genetic testing (CLARIFIDE Plus, INHERIT Select, Basepaws), and licensing/distribution partnerships such as the Orion Oyj arrangement for Tessie.

The company operates a "science-to-scale" R&D and manufacturing model anchored by approximately 1,700 R&D colleagues, ten R&D centers co-located with manufacturing sites, 21 manufacturing facilities across 11 countries, and a global distribution network of 60+ centers. Cumulative R&D investment since 2013 is approximately $6 billion, producing 18 blockbuster products (>$100M in annual revenue each) and 2,000+ lifecycle innovations over the past 13 years. Recent corporate development activity includes the acquisitions of Jurox (2021), PetMedix (2023, ~$210M), Adivo (2023), Basepaws (2022), Veterinary Pathology Group (2025), and the pending Neogen animal genomics business / GeneSeek ($160M, announced March 2026). FY2025 revenue was approximately $9.47 billion with 2026 guidance of $9.825B-$10.025B; however, US companion animal sales fell 11% in Q1 2026 amid lower clinic traffic and competitive pressure, leading to lowered guidance and securities class action lawsuits over the January 2025–May 2026 class period.

Name

Zoetis

Legal name

Zoetis Inc.

Website

https://zoetis.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Zoetis is the world's leading animal health company, developing and commercializing medicines, vaccines, diagnostics, and biologics—including proprietary monoclonal antibody therapies—across 8 species for veterinarians, livestock producers, and pet owners in 100+ countries.

Ownership category

akta.pro rank

Product category

Animal Health Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Dog and Cat Food Manufacturing (311111)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Companion Animal Therapeutics (Rx) (HLAMAEAA)

akta.pro secondary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

Keywords

• Animal health products
• Veterinary pharmaceuticals
• Livestock vaccines
• Companion animal biologics
• Veterinary diagnostics

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices24 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Companion Animal Product Sales: Sales of vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals (dogs, cats, horses). Includes blockbuster products Librela (mAb for canine OA pain), Simparica Trio (parasiticide), Apoquel (oclacitinib for allergic dermatitis), Cytopoint (lokivetmab mAb), Solensia (feline OA pain mAb), and Revolution Plus. Includes both one-time purchases and recurring diagnostic consumables.
2. Livestock Product Sales: Sales of vaccines, parasiticides, anti-infectives, and other animal health products for livestock including beef and dairy cattle, pigs, poultry, sheep, and fish. Key products include Draxxin KP, BOVI-SHIELD, EXCEDE, INFORCE 3, FOSTERA PRRS, and Poulvac E. Coli.
3. Diagnostics Recurring Revenue: Recurring revenue from diagnostic consumables, reference laboratory services (U.S. only), and AI-powered diagnostic analyzer placements (Vetscan OptiCell, Vetscan Imagyst, Vetscan VS2, Vetscan HM5, Vetscan & Witness rapid tests, AlphaTrak 3). Strong recurring flywheel driven by consumables and software updates.
4. Genetic Testing & Precision Animal Health Services: Fee-based genomic testing services including INHERIT Select, CLARIFIDE Plus, and Basepaws Breed + Health tests providing predictions across 21 economically important traits for cattle, dogs, and cats.
5. Licensing & Distribution Partnerships: Revenue from licensing and distribution partnerships such as the agreement with Orion Oyj to commercialize Tessie (tasipimidine) for canine noise aversion and separation anxiety in the U.S. market, leveraging Zoetis's established U.S. distribution network.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Core offering

Zoetis manufactures and sells a broad portfolio of animal health products including vaccines, parasiticides, anti-infectives, dermatology therapies, monoclonal antibody (mAb) biologics, and AI-powered diagnostic analyzers for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, sheep, fish). The company also provides genomic testing services, digital clinical decision support via the Virtual Laboratory, and reference laboratory services in the United States. Products are sold primarily to veterinarians and livestock producers through a direct field sales force and global distribution network spanning 100+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• PHARMAQ: Global leader in fish health and vaccines (aquaculture), part of Zoetis since 2015. Provides vaccines, therapeutics, vaccination equipment, and diagnostics for the aquaculture industry.
• Vetscan
• Basepaws
• Zoetis Foundation

Products and services

• Librela First monoclonal antibody (mAb) therapy approved to treat osteoarthritis (OA) pain in dogs; flagship canine OA pain biologic in Zoetis' portfolio and centerpiece of its mAb franchise for veterinarians.
• Simparica Trio Triple-combination monthly chewable parasiticide for dogs providing combined protection against heartworm disease, ticks and fleas, roundworms, and hookworms; sold to veterinarians.
• Apoquel / Apoquel Chewable FDA-approved oclacitinib tablet and chewable tablet for control of pruritus associated with canine allergic dermatitis; key canine dermatology product sold to veterinarians.
• Solensia Monoclonal antibody therapy for the control of osteoarthritis pain in cats; extends Zoetis' mAb-based OA pain franchise to the feline segment, sold to veterinarians.
• Cytopoint Injectable lokivetmab (monoclonal antibody) therapy for the treatment of atopic dermatitis in dogs targeting interleukin-31 (IL-31); cornerstone of Zoetis' canine dermatology franchise sold to veterinarians.
• Revolution Plus Topical parasiticide combination (selamectin and sarolaner) for cats providing protection against fleas, ticks, ear mites, roundworms, and hookworms; key feline parasiticide product sold to veterinarians.
• Draxxin KP Injectable combination solution of tulathromycin antibiotic and ketoprofen NSAID for beef and dairy cattle; flagship livestock pharmaceutical for bovine respiratory disease and associated inflammation sold to livestock producers and veterinarians.
• Vetscan OptiCell First-of-its-kind cartridge-based hematology analyzer that combines viscoelastic focusing (VEF) and AI technology to provide complete blood count (CBC) analysis at the point of care, including CHCM; sold to veterinary clinics.
• Vetscan Imagyst Compact AI-powered veterinary diagnostic analyzer offering six testing capabilities (parasitology, fecal analysis, and others) with expert-level deep learning image analysis results delivered within minutes; sold to veterinary clinics.
• Zoetis Virtual Laboratory Integrated support network pairing best-in-class AI with board-certified veterinary specialists to provide actionable diagnostic and treatment insights for veterinarians across specialty areas including dermatology.
• Zoetis Reference Laboratories Reference laboratory diagnostic testing services offered to veterinary clinics in the United States; complements Zoetis' in-clinic diagnostic analyzer portfolio.
• INHERIT Select Commercial genetic testing service providing predictions across 21 economically important traits for beef cattle, including bovine respiratory disease health and survival indicators; sold to livestock producers and veterinarians.
• CLARIFIDE Plus Genomic testing product for dairy cattle providing genetic predictions to support breeding, herd health, and productivity decisions; sold to dairy producers and veterinarians.

Quantifiable outcome

• 18 blockbuster products earning $100M+ in revenue each (2025)
• +9 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered core (distribution partnership for u.s. product launch), core (major acquisition in precision animal health), core (acquisition enhancing diagnostics in uk/ireland), core (acquisition adding antibody platform), core (acquisition enhancing product portfolio and australian presence), core (industry partnership for veterinary education), major (founding coalition member) and minor (brazilian pet ecosystem commercial partner).

• Orion Oyjcore (distribution partnership for u.s. product launch)OEM/ Whitelabel/ Licensing Partner · 19 May 2026Orion Oyj received FDA approval for Tessie (tasipimidine), its proprietary veterinary drug for treating noise aversion and separation anxiety in dogs. The product will be commercialized in the U.S. market through partner Zoetis, placing it alongside existing behavioral medications Sileo and Bonqat in Zoetis' companion-animal portfolio. The arrangement leverages Zoetis' established U.S. distribution network without requiring Orion to build its own commercial infrastructure.
• Neogen Corporation (GeneSeek animal genomics business)core (major acquisition in precision animal health)Strategic or Co-development Partner · 2 March 2026Zoetis and Neogen Corporation signed a definitive agreement on May 3, 2026 for Zoetis to acquire Neogen's animal genomics business, GeneSeek, for $160 million. GeneSeek operates five laboratories across the United States, Brazil, Australia, China, and the United Kingdom, serving customers in more than 120 countries, and generated approximately $90 million in sales during fiscal year 2025. The deal is expected to close in the second half of 2026 and is part of Neogen's strategy to simplify its portfolio and focus on core food and animal safety markets while accelerating debt reduction.
• Veterinary Pathology Group (VPG)core (acquisition enhancing diagnostics in uk/ireland)Strategic or Co-development Partner · 11 November 2025Veterinary Pathology Group (VPG) became part of Zoetis on November 11, 2025 to enhance veterinary diagnostics and provide improved testing capabilities across the UK and Ireland. The merger aims to deliver faster, more accurate diagnostic solutions with strengthened local support.
• PetMedix Ltdcore (acquisition adding antibody platform)Strategic or Co-development Partner · 15 September 2023Zoetis Inc. acquired PetMedix Ltd on September 15, 2023 in a deal valued at approximately $210 million. PetMedix is a UK-based biotech company specializing in species-specific therapeutic antibodies for pets. The purchase included upfront cash, cash considerations for milestones, and contingent payments based on achievement of certain milestones. PetMedix continues operations as an innovation hub in Europe.
• Juroxcore (acquisition enhancing product portfolio and australian presence)Strategic or Co-development Partner · 4 August 2021Zoetis announced the acquisition of Jurox on August 4, 2021. Jurox is a provider and manufacturer of livestock and companion animal products based in Australia. The deal aims to enhance Zoetis' product offerings, manufacturing capacity, and international growth prospects, particularly in Australia.
• World Small Animal Veterinary Association (WSAVA)core (industry partnership for veterinary education)Strategic or Co-development PartnerWSAVA and Zoetis have partnered to create a Certificate in Pain Management for veterinarians and veterinary technicians. The course promotes the importance of managing companion animal pain to protect the human-animal bond, and is comprised of three modules: Understanding and assessing pain, Preventing and treating pain, and Pain management in practice. The course is accessible via wsava.talentlms.com.
• Human Animal Bond Research Institute (HABRI)major (founding coalition member)Strategic or Co-development PartnerZoetis is a founding partner of The Pets and Families Housing Coalition, formed at HABRI's third-annual Spring Policy Forum in Washington on pet-inclusive housing. Other founding partners include the American Pet Products Association (APPA), Independence Pet Holdings (IPH), Mars, the Michelson Center for Public Policy (MCPP), and HABRI. The coalition will advocate for policies such as prohibiting breed and size restrictions on pets, capping excessive pet rents and deposits, and mandating pet policy transparency in apartment leasing.
• Petloveminor (brazilian pet ecosystem commercial partner)GTM or Marketing PartnerPetlove, Brazil's largest pet ecosystem, launched PetVet medication benefits program offering up to 40% discounts on approximately 140 veterinary medications. Zoetis is one of the major pharmaceutical partners (alongside Elanco, Virbac, Biovet, and Ourofino) targeting the R$ 3.2 billion veterinary medications segment projected to grow 9-11% annually until 2034.

Scale indicators20 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Elanco Animal Health: Direct competitor in animal health pharmaceuticals and vaccines across companion animal and livestock. Elanco competes head-to-head with Zoetis across parasiticides, dermatology, pain, and vaccines, and is the most comparable public animal health pure-play.
• Dechra Pharmaceuticals: UK-based specialist veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology, and pain management. Recently taken private by EQT; direct peer to Zoetis in companion animal specialty therapeutics.
• Virbac: Independent global animal health company headquartered in France, offering vaccines, parasiticides, and pharmaceuticals for companion and production animals. Direct peer with comparable product portfolio and global reach, though smaller scale than Zoetis.
• Vetoquinol: Independent French animal health company focused on companion animals and livestock. Direct peer in veterinary pharmaceuticals, competing in similar therapeutic categories and geographic markets.
• IDEXX Laboratories: Leading veterinary diagnostics company providing in-clinic analyzers, reference lab services, and software. Directly comparable to Zoetis' Vetscan diagnostics platform and reference lab business, competing for the same veterinarian customers.
• Ceva Santé Animale: Private global animal health company headquartered in France. Competes with Zoetis across vaccines, pharmaceuticals, and companion animal products; comparable in geographic reach and product portfolio depth.
• Phibro Animal Health: Animal health and nutrition company focused on livestock (cattle, poultry, swine). Directly comparable to Zoetis' livestock segment with nutritional specialty products and pharmaceuticals competing for the same producer customers.

Broad incumbents

• Merck Animal Health: Animal health division of Merck & Co. (MRK), a direct competitor across vaccines, parasiticides, and pharmaceuticals. Larger parent organization and broader R&D resources make it a broad incumbent in the same overall animal health market.
• Boehringer Ingelheim Animal Health: Animal health division of Boehringer Ingelheim, one of the world's largest animal health companies. Direct competitor in vaccines, parasiticides, and therapeutics; broad incumbent with portfolio overlap across companion animal and livestock segments.

Emerging players

• Antech Diagnostics (Mars Petcare): Veterinary diagnostics and reference lab business within Mars Petcare, including recently acquired Heska. Competes with Zoetis Reference Laboratories and Vetscan platform in the diagnostics segment with growing scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/zoetis
• YouTubeyoutube.com/@ZoetisInc
• Facebookfacebook.com/zoetis
• LinkedInlinkedin.com/company/zoetis

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zoetis